This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price.
Rory Martin, PhD
Advertisement
Rory Martin, PhD, Gross to Net and 340B Analytics & Thought Leadership, IQVIA Market Access Technology Solutions
ORCID ID: 0000-0002-7216-4245
Articles by Rory Martin, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
2
Patients Face New Care Complexities as DTC Options Expand
3
Expiring ACA Subsidies and CMS Payment Models Raise Costs for Consumers and Employers
4
Louisiana Delivers Innovative Cancer Treatments, but Ensuring Access Is a Work in Progress
5
